Hemab Therapeutics (NASDAQ:COAG) Raised to “Strong-Buy” at The Goldman Sachs Group

Hemab Therapeutics (NASDAQ:COAG) was upgraded by equities researchers at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other analysts have also issued reports on the stock. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $42.00 target price on the stock. Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $39.00 target price on the stock. Finally, Evercore started coverage on shares of Hemab Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $50.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Strong Buy” and a consensus price target of $41.75.

Hemab Therapeutics Trading Up 7.5%

Shares of NASDAQ COAG opened at $27.84 on Tuesday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. purchased 3,802 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 19th. The shares were acquired at an average cost of $24.97 per share, with a total value of $94,935.94. Following the purchase, the insider owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. The trade was a 0.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have bought 2,902,872 shares of company stock worth $53,769,784 in the last ninety days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.